Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: An evidence-based review

Guy El Helou, Raymund R Razonable

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) is a leading opportunistic infection in immune compromised patients, including allogeneic hematopoietic stem cell (HSCT) or solid organ transplant (SOT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. Letermovir, a novel CMV viral terminase inhibitor drug, was recently approved for CMV prophylaxis in allogeneic HSCT recipients. It has a favorable pharmacokinetic and tolerability profile. The aim of this paper is to review the evidence supporting the use of letermovir in allogeneic HSCT recipients, and how the drug impacts our contemporary clinical practice. In addition, we discuss the ongoing clinical trial of letermovir for the prevention of CMV in SOT recipients. The use of letermovir for treatment of CMV infection and disease is not yet approved. However, because of a unique mechanism of activity, we provide our perspective on the potential role of letermovir in the treatment of ganciclovir-resistant CMV infection and disease. Furthermore, drug-resistant CMV has emerged during use of letermovir for prophylaxis and treatment. Caution is advised on its use in order to preserve its therapeutic lifespan.

Original languageEnglish (US)
Pages (from-to)1481-1491
Number of pages11
JournalInfection and Drug Resistance
Volume12
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cytomegalovirus Infections
Cytomegalovirus
Antiviral Agents
Pharmaceutical Preparations
Foscarnet
Transplants
Ganciclovir
Opportunistic Infections
Leukopenia
Therapeutics
Hematopoietic Stem Cells
Neutropenia
Drug-Related Side Effects and Adverse Reactions
AIC246
Transplant Recipients
Pharmacokinetics
Clinical Trials
Morbidity
Mortality
Infection

Keywords

  • Cytomegalovirus
  • Letermovir
  • Transplantation
  • UL56
  • UL97
  • Valganciclovir

ASJC Scopus subject areas

  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients : An evidence-based review. / El Helou, Guy; Razonable, Raymund R.

In: Infection and Drug Resistance, Vol. 12, 01.01.2019, p. 1481-1491.

Research output: Contribution to journalReview article

@article{40bf0abf6bc144cb82af7964c1b836c0,
title = "Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: An evidence-based review",
abstract = "Cytomegalovirus (CMV) is a leading opportunistic infection in immune compromised patients, including allogeneic hematopoietic stem cell (HSCT) or solid organ transplant (SOT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. Letermovir, a novel CMV viral terminase inhibitor drug, was recently approved for CMV prophylaxis in allogeneic HSCT recipients. It has a favorable pharmacokinetic and tolerability profile. The aim of this paper is to review the evidence supporting the use of letermovir in allogeneic HSCT recipients, and how the drug impacts our contemporary clinical practice. In addition, we discuss the ongoing clinical trial of letermovir for the prevention of CMV in SOT recipients. The use of letermovir for treatment of CMV infection and disease is not yet approved. However, because of a unique mechanism of activity, we provide our perspective on the potential role of letermovir in the treatment of ganciclovir-resistant CMV infection and disease. Furthermore, drug-resistant CMV has emerged during use of letermovir for prophylaxis and treatment. Caution is advised on its use in order to preserve its therapeutic lifespan.",
keywords = "Cytomegalovirus, Letermovir, Transplantation, UL56, UL97, Valganciclovir",
author = "{El Helou}, Guy and Razonable, {Raymund R}",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/IDR.S180908",
language = "English (US)",
volume = "12",
pages = "1481--1491",
journal = "Infection and Drug Resistance",
issn = "1178-6973",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients

T2 - An evidence-based review

AU - El Helou, Guy

AU - Razonable, Raymund R

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cytomegalovirus (CMV) is a leading opportunistic infection in immune compromised patients, including allogeneic hematopoietic stem cell (HSCT) or solid organ transplant (SOT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. Letermovir, a novel CMV viral terminase inhibitor drug, was recently approved for CMV prophylaxis in allogeneic HSCT recipients. It has a favorable pharmacokinetic and tolerability profile. The aim of this paper is to review the evidence supporting the use of letermovir in allogeneic HSCT recipients, and how the drug impacts our contemporary clinical practice. In addition, we discuss the ongoing clinical trial of letermovir for the prevention of CMV in SOT recipients. The use of letermovir for treatment of CMV infection and disease is not yet approved. However, because of a unique mechanism of activity, we provide our perspective on the potential role of letermovir in the treatment of ganciclovir-resistant CMV infection and disease. Furthermore, drug-resistant CMV has emerged during use of letermovir for prophylaxis and treatment. Caution is advised on its use in order to preserve its therapeutic lifespan.

AB - Cytomegalovirus (CMV) is a leading opportunistic infection in immune compromised patients, including allogeneic hematopoietic stem cell (HSCT) or solid organ transplant (SOT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. Letermovir, a novel CMV viral terminase inhibitor drug, was recently approved for CMV prophylaxis in allogeneic HSCT recipients. It has a favorable pharmacokinetic and tolerability profile. The aim of this paper is to review the evidence supporting the use of letermovir in allogeneic HSCT recipients, and how the drug impacts our contemporary clinical practice. In addition, we discuss the ongoing clinical trial of letermovir for the prevention of CMV in SOT recipients. The use of letermovir for treatment of CMV infection and disease is not yet approved. However, because of a unique mechanism of activity, we provide our perspective on the potential role of letermovir in the treatment of ganciclovir-resistant CMV infection and disease. Furthermore, drug-resistant CMV has emerged during use of letermovir for prophylaxis and treatment. Caution is advised on its use in order to preserve its therapeutic lifespan.

KW - Cytomegalovirus

KW - Letermovir

KW - Transplantation

KW - UL56

KW - UL97

KW - Valganciclovir

UR - http://www.scopus.com/inward/record.url?scp=85068793079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068793079&partnerID=8YFLogxK

U2 - 10.2147/IDR.S180908

DO - 10.2147/IDR.S180908

M3 - Review article

AN - SCOPUS:85068793079

VL - 12

SP - 1481

EP - 1491

JO - Infection and Drug Resistance

JF - Infection and Drug Resistance

SN - 1178-6973

ER -